

Amgen Inc.
Reconciliation of historical GAAP net income (loss) to "Adjusted" net income
(In millions)
(Unaudited)

	Historical results for the years ended December 31,				
	2000	2001	2002	2003	2004
GAAP net income (loss)	\$ 1,139	\$ 1,120	\$ (1,392)	\$ 2,259	\$ 2,363
Adjustments to GAAP net income (loss):					
Write-off of acquired in-process research and development.....	30	-	2,992 (1)	-	554 (2)
Amortization of acquired intangible assets.....	-	-	155 (1)	336 (1)	333 (1)
Other merger related expenses.....	-	-	87 (1)	70 (1)	53 (1)(2)
Legal settlement.....	-	-	-	47	(11)
Legal awards and cost recoveries.....	(74)	-	(151)	(74)	-
Amgen Foundation contribution.....	25	-	50	50	-
Termination of collaboration agreements.....	-	203	(40)	-	-
Other.....	-	40	-	-	-
Tax effects of the above adjustments.....	19	(85)	(39)	(149)	(144)
"Adjusted" net income	<u>\$ 1,139</u>	<u>\$ 1,278</u>	<u>\$ 1,662</u>	<u>\$ 2,539</u>	<u>\$ 3,148</u>

Notes:

- (1) Incurred in connection with the Immunex Corporation acquisition in July 2002.
- (2) Incurred in connection with the Tularik Inc. acquisition in August 2004.